Sign in

CIK 0001590877

  • Non-accelerated filer
  • Smaller reporting company

REGENXBIO Inc.

Sign in to watch
Ticker
RGNX
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Entity type
Operating
EIN
471851754
Phone
+1 240-552-8181
Business address
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850
Former names
ReGenX Biosciences, LLC
  1. 4 Open-market sale President and CEO sold 1,500 shares at $42.19 ($63,285)
  2. 4 Open-market sale Director sold 48,233 shares at $45.04 ($2,172,323)
  3. 4 Open-market sale President and CEO sold 38,000 shares at an average $44.71 ($1,698,910)
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 3 Insider Initial Statement of Ownership
  8. 4 Exercise or conversion Chief Financial Officer acquired 10,000 shares (option exercise)
  9. 4 Open-market sale President and CEO sold 6,000 shares at an average $40.08 ($240,465)
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Derivatives Options or other derivatives
  15. 4 Derivatives Options or other derivatives
  16. 4 Derivatives Options or other derivatives
  17. 4 Open-market sale President and CEO sold 1,500 shares at $40.77 ($61,155)
  18. 4 Open-market sale Chief Legal Officer sold 4,701 shares at $49.08 ($230,725)
  19. 4 Open-market sale Chief Legal Officer sold 1,300 shares at $49.11 ($63,843)
  20. 4 Open-market sale Chief Legal Officer sold 10,000 shares at an average $44.79 ($447,880)

Page 8 of 22 · 435 filings